上海荣泰健康科技股份有限公司 2024 年年度股东大会 会议资料 中国·上海 二〇二五年五月 上海荣泰健康科技股份有限公司 2024 年年度股东大会会议资料 上海荣泰健康科技股份有限公司 2024 年年度股东大会会议议程 一、会议时间 现场会议：2025 年 5 月 14 日（星期三）14：00 网络投票：2025 年 5 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 二、现场会议地点 上海市青浦区徐泾镇高光路169弄虹桥时代广场6号楼荣泰大厦公司会议室 4、审议《关于公司 2024 年度财务报告的议案》 5、审议《关于公司 2024 年度财务决算报告的议案》 6、审议《关于公司 2024 年度利润分配预案的议案》 上海荣泰健康科技股份有限公司 ...

A股脑机接口板块盘初上升，爱朋医疗涨超8%，诚益通、荣泰健康翔宇医疗等涨超5%，狄耐克、三博 脑科等跟涨。 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [5] Core Viewpoints - The company experienced a temporary decline in performance, with a 13.92% year-on-year decrease in revenue for 2024, totaling 1.597 billion yuan. The net profit attributable to shareholders was 192 million yuan, down 5.31% year-on-year [2][9] - The company is actively expanding into new business areas, including automotive seating and AI-enabled products, to drive growth despite current market challenges [9] - The company has established strategic partnerships, including a collaboration with a leading global parts supplier and a joint project with Shanghai Jiao Tong University to develop an AI model for health applications [9] Financial Performance Summary - For 2024, the company reported total revenue of 1.597 billion yuan, a decrease of 13.92% year-on-year. The net profit attributable to shareholders was 192 million yuan, down 5.31% year-on-year, and the net profit after deducting non-recurring gains and losses was 163 million yuan, down 12.47% year-on-year [2][9] - In Q4 2024, the company achieved revenue of 433 million yuan, a decline of 22.34% year-on-year, with a net profit of 49 million yuan, down 3.02% year-on-year [2][9] - For Q1 2025, the company reported revenue of 395 million yuan, a slight decrease of 1.41% year-on-year, with a net profit of 44 million yuan, down 29.97% year-on-year [2][9] Product and Market Analysis - The company's revenue decline is attributed to weak market demand and intensified competition. Revenue from massage chairs and small massage appliances fell by 14.05% and 28.64% respectively, while experiential massage services saw a slight increase of 0.76% [9] - Domestic sales decreased by 20.17%, while international sales fell by 10.25%. The company is seeing varied performance across different international markets, with significant growth in its cross-border e-commerce business [9] Future Outlook - The company is expected to recover and achieve faster growth as market demand stabilizes. Projections for net profit attributable to shareholders for 2025, 2026, and 2027 are 172 million yuan, 194 million yuan, and 214 million yuan respectively, with corresponding price-to-earnings ratios of 23.81, 21.12, and 19.11 [9]

Core Viewpoint - Rongtai Health reported a decline in revenue and net profit for 2024, with a significant drop in Q4 and Q1 of 2025, while maintaining a high dividend payout ratio of 59.3% [1][4] Financial Performance - 2024 revenue, net profit attributable to shareholders, and net profit excluding non-recurring items were 1.6 billion, 190 million, and 160 million yuan, respectively, representing year-on-year declines of 14%, 5%, and 12% [1] - Q4 2024 figures were 430 million, 50 million, and 40 million yuan, with year-on-year declines of 22%, 3%, and 30% [1] - Q1 2025 figures were 390 million, 40 million, and 30 million yuan, with year-on-year changes of -1%, -30%, and -47% [1] Sales Performance - In 2024, revenue from massage chairs, small massage appliances, and experiential massage services were 1.52 billion, 50 million, and 5 million yuan, with year-on-year changes of -14%, -29%, and +0.8% [2] - Domestic and overseas market revenues in 2024 were 650 million and 920 million yuan, with year-on-year declines of 20% and 10% [2] - The overseas market showed mixed results, with declines in Korea and the US, while Europe and the Middle East saw stable growth [2] Profitability Metrics - Gross margin for 2024 and Q1 2025 were 31.7% and 32.5%, with year-on-year changes of +1.1 and -3.0 percentage points [3] - Expense ratios for sales, management, R&D, and financial expenses in 2024 were 11.3%, 5.4%, 5.0%, and -1%, with year-on-year changes of +0.5, +1.2, +0.7, and -0.2 percentage points [3] - Net profit margin for 2024, Q4 2024, and Q1 2025 were 12%, 11.4%, and 11.1%, with year-on-year changes of +1.1, +2.3, and -4.5 percentage points [3] Investment Outlook - The company is a leader in the domestic massage chair industry, focusing on channel reform and online content investment, with expected benefits from national subsidy policies in 2025 [4] - The company is expanding overseas and exploring new business areas such as automotive lightweight massage components and smart home devices [4] - The new employee stock ownership plan reflects long-term confidence in development, with projected net profits of 210 million and 240 million yuan for 2025 and 2026, corresponding to EPS of 1.2 and 1.3 yuan [4]

Investment Rating - The report maintains a "Buy" rating for the company, Rongtai Health (603579) [1][8] Core Views - The company has shown a recovery in gross margin in Q1 2025, with a focus on the DeepHealth smart health model, automotive scenarios, and new forms of robotic hands, indicating potential for growth [1][8] - The company reported a total revenue of 1.597 billion yuan in 2024, a decrease of 13.92%, and a net profit of 192 million yuan, down 5.31% [4][5] - The Q1 2025 revenue was 395 million yuan, a decline of 1.41%, with a net profit of 44 million yuan, down 29.97% [4][5] Summary by Sections Financial Performance - In 2024, the company's revenue from massage chairs and small massage appliances was 1.518 billion yuan and 51 million yuan, respectively, with year-on-year declines of 14.05% and 28.64% [5] - Domestic and overseas revenues in 2024 were 652 million yuan and 923 million yuan, respectively, with declines of 20.17% and 10.25% [5] - The gross margin improved from 29.66% in Q4 2024 to 32.54% in Q1 2025, an increase of 2.88 percentage points [6] - The net profit margin decreased from 11.33% in Q4 2024 to 11.14% in Q1 2025 [6] Product and Market Development - The company is expanding into automotive massage products and has established a subsidiary for this purpose, collaborating with Faurecia China [7] - A partnership with Shanghai Jiao Tong University aims to enhance product capabilities through AI [7] - The company anticipates growth in overseas markets, particularly in Europe and the Middle East, with a strong performance in cross-border e-commerce [5][7] Future Projections - The company expects net profits of 200 million yuan in 2025, 221 million yuan in 2026, and 246 million yuan in 2027, with corresponding EPS of 1.13, 1.25, and 1.39 yuan [8] - The projected revenue growth rates for 2025, 2026, and 2027 are 3.10%, 10.50%, and 10.70%, respectively [8]

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 29.75 CNY for the next six months [5]. Core Views - The company reported a revenue of 1.6 billion CNY in 2024, a year-over-year decrease of 13.9%, and a net profit attributable to shareholders of 190 million CNY, down 5.3% year-over-year. The revenue for Q4 2024 was 430 million CNY, down 22.3% year-over-year, while the net profit for the same quarter was 50 million CNY, down 3.0% year-over-year. In Q1 2025, the company achieved a revenue of 390 million CNY, a slight decrease of 1.4% year-over-year, with a net profit of 40 million CNY, down 30.0% year-over-year [2][3]. Summary by Sections Revenue Performance - The company's Q1 revenue decline has narrowed, with domestic sales benefiting from the old-for-new subsidy policy, leading to improved consumption of massage chairs. Online sales for the company's brands increased by 7.4% year-over-year in Q1 [3]. - The company has established a strategic partnership with a leading global parts supplier, which is expected to enhance its automotive massage seat business [3]. Profitability - The net profit margin for Q1 was 11.1%, a decrease of 4.5 percentage points year-over-year. This decline in profitability is attributed to a decrease in gross margin and an increase in financial expense ratio due to currency exchange losses [3]. Cash Flow - The operating cash flow for Q1 improved, with a net outflow of 30 million CNY compared to 150 million CNY in the same period last year. The cash collection from sales increased by 8.6% year-over-year, and inventory levels decreased by 23.4% year-over-year [4]. Future Outlook - The company is expected to see a recovery in domestic sales as consumer sentiment improves, and overseas sales are anticipated to continue rising. The projected EPS for 2025, 2026, and 2027 are 1.19 CNY, 1.38 CNY, and 1.58 CNY respectively [4][5].

特此公告。 上海荣泰健康科技股份有限公司董事会 2025 年 4 月 26 日 上海荣泰健康科技股份有限公司 关于公司通过高新技术企业复审的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海荣泰健康科技股份有限公司（以下简称"公司"）于近日收到由上海市 科学技术委员会、上海市财政局、国家税务总局上海市税务局联合颁发的《高 新技术企业证书》（证书编号：GR202431005568，发证时间：2024 年 12 月 26 日），有效期三年。本次系公司原高新技术企业证书有效期满后进行的重新认定。 根据《中华人民共和国企业所得税法》以及国家关于高新技术企业的相关税收 规定，公司（不含子公司）自本次通过高新技术企业复审后连续三年（2025 年 至 2027 年）将继续享受国家关于高新技术企业的相关优惠政策，按 15%的企业 所得税税率缴纳企业所得税。鉴于 2024 年公司已按 15%的企业所得税税率进行 纳税申报及预缴，故本次通过高新技术企业复审所获税收优惠政策不会对公司 2024 年度经营业绩产生影响。 证券代码：603579 ...

Core Viewpoint - The collaboration between Rongtai Health and Forvia has led to the development of the revolutionary 3D "Zen" seat, which integrates professional massage chair technology into automotive seating, marking a new era in in-car health experiences [2][3]. Group 1: Product Features - The 3D "Zen" seat features a unique dual-ball linkage structure that replicates core massage techniques such as kneading, tapping, and gripping within a limited space [2]. - The seat includes a specially designed hidden massage head that is fully retracted when not in use, balancing functionality with aesthetic space considerations [2]. - It operates on a fully mechanical structure, providing stronger massage intensity compared to pneumatic systems while maintaining noise levels below 30dB, aligning with the quiet characteristics of new energy vehicles [2]. - The patented collapse mechanism design has passed stringent automotive seat safety standards, ensuring passenger safety under extreme conditions [2]. - The product has completed durability and functionality testing and offers a comprehensive solution for all comfort function needs, with market launch expected by the end of the year [2]. Group 2: Strategic Collaboration - Rongtai Health's General Manager Lin Qi emphasized that the strategic partnership with Forvia is a significant milestone for the company's "technology going global" initiative [3]. - The collaboration aims to empower more international automotive companies with Rongtai's health technology, providing enhanced health solutions for global users [3]. - The 3D "Zen" seat is set to redefine travel scenarios and lead new technologies in in-car massage functions, potentially reshaping the competitive landscape of high-end intelligent cockpits globally [3].

Core Viewpoint - The company, Shanghai Rongtai Health Technology Co., Ltd., reported a decline in revenue and profit for the year, with a focus on the massage equipment industry, which is experiencing both challenges and opportunities due to market dynamics and regulatory changes [22][10][9]. Company Overview - The company operates in the massage equipment industry, classified under specialized equipment manufacturing [5]. - Its main products include massage chairs and portable massage devices, aimed at providing health and relaxation benefits to users [10][11]. Industry Analysis - The massage chair industry has evolved through various stages, from initial development in the 1980s to a mature market characterized by intense competition and increased consumer expectations [6][7]. - The global market for massage equipment is steadily growing, with the Asia-Pacific region, particularly China and Southeast Asia, being key drivers [6]. - Recent policies promoting health and consumption are expected to benefit the industry, while international trade challenges may pose risks [8][9]. Financial Performance - For the reporting period, the company achieved a consolidated revenue of approximately 1.60 billion yuan, a decrease of 13.92% year-on-year, and a net profit of approximately 192 million yuan, down 5.31% from the previous year [22]. - The decline in financial performance aligns with broader industry trends and consumer behavior shifts [20]. Market Position - The company is recognized as a leading player in the domestic massage chair market and a significant manufacturer globally, leveraging its 28 years of experience in research and development [18]. - It employs a differentiated branding strategy with two main brands targeting different market segments, enhancing its market share [18]. Sales and Distribution - The company utilizes a multi-channel sales approach, including direct sales, e-commerce, and ODM for international markets, allowing it to adapt to varying consumer preferences [12][13][14]. - The domestic market strategy focuses on self-owned brands, while the international strategy emphasizes ODM partnerships [12][14]. Regulatory Environment - Recent regulations, including the IEC standard for massage equipment safety, and national policies promoting health consumption, are expected to positively impact the industry [8][9]. - The ongoing "Healthy China 2030" initiative continues to support the health industry, including massage equipment, through various incentives [9].

证券代码：603579 证券简称：荣泰健康 公告编号：2025-028 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 14 日 14 点 00 分 召开地点：上海市青浦区徐泾镇高光路 169 弄虹桥时代广场 6 号楼荣泰大 股东大会召开日期：2025年5月14日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 厦公司会议室 (五)网络投票的系统、起止日期和投票时间。 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 14 日 至2025 年 5 月 14 日 采用上海证券交易所网 ...